 that we have now one year after the pandemic had started, several effective vaccines available and already approved in Europe. And this is a great achievement of translational and clinical research to get in this short period of time, although it seems so long for all of us. This output that we have now the possibility to vaccinate the people all over the world and here in Europe after approval of the vaccines, now for vaccines by the European Medical Agency. The principle of showing that a vaccine is effective is that you vaccinate against placebo, a population, and then you see under the daily circumstances of this specific population, how many infections you can document and how severe those infections are. And this is the principle the vaccines were based on. Due to the shortness of time, the vaccines were evaluated in healthy volunteers and those persons were not necessarily patients. Regarding the study population, we have to claim that only a minority of patients, for example, 3% of those who were vaccinated in the first Biontech Pfizer trial had a cancer history. However, we have a lot of experience for vaccinations in cancer and especially in myeloma patients. And we know that myeloma leads to an immunosuppression and that the probability of severe infections per se is higher than in non-myeloma affected patients. And we know very well how effective pneumococcal and influenza vaccinations are for myeloma patients and how important. We know that in immunosuppressed patients, also in myeloma patients, there are sometimes infections despite the vaccination. However, for influenza, for example, we know that those infections then have a milder cause normally and so that the vaccine cannot prevent from being infected but can prevent effectively still for having a severe disease cause for the need of mechanical ventilation and so on. And we translate this experience very clearly to the now available COVID vaccines. The International Myeloma Society, the International Myeloma Working Group, the European Hematological Association and all country specific hematologic and oncology associations clearly stated a yes for all myeloma patients being vaccinated against COVID. And this is a clear yes and a clear yes for all approved vaccines. The vaccines approved are different, different in the basis we have two mRNA vaccines, the Biontech Pfizer and the Moderna vaccine and we have two protein-based vaccinations, the AstraZeneca and the Johnson & Johnson vaccine. All have advantages and probably also disadvantage but they all are very effective in protecting from infection, from being infectious and especially having a severe disease cause so with the need of intensive care or mechanical ventilation or even ultimately that COVID is leading to them. We know that myeloma patients have a higher risk for severe COVID infections and disease courses and that this accounts especially for patients with the very active myeloma disease. So that our clear recommendation is that any single myeloma patients should receive as soon as possible and as soon as it is available for each individual patient a vaccination against COVID and we recommend any single approved vaccine and we hope that the infrastructures will be providing the vaccine now very, very fast to our patients at need.